Switching Therapy and New and Emerging Agents in DRP

, ,

Key opinion leaders explore the clinical and economic burden of dementia-related psychosis and the unmet medical need.

The unmet needs in the available treatment options for dementia-related psychosis are discussed along with the role of adverse events in switching therapies. Next, Gary W. Small, MD, discusses strategies for educating patients and caregivers on treatment options and managing their expectations and shares current research focus to develop a treatment for dementia-related psychosis. Finally, Stephen A. Brunton, MD, reviews important resources to guide decision-making for dementia-related psychosis.

The speakers are paid consultants on behalf of Acadia Pharmaceuticals Inc. This is a disease-awareness, non-CME program sponsored by Acadia Pharmaceuticals Inc.

Click here to watch the previous video in this series.

Click here to watch the next video in this series.